Pharmacogenetics of CYP3A5 on Carbamazepine pharmacokinetics in epileptic patients developing toxicity by Mubarak Al-Gahtany et al.
POSTER PRESENTATION Open Access
Pharmacogenetics of CYP3A5 on Carbamazepine
pharmacokinetics in epileptic patients developing
toxicity
Mubarak Al-Gahtany1*, Gauthaman Karunakaran2, Murali Munisamy2*
From 2nd International Genomic Medical Conference (IGMC 2013)
Jeddah, Kingdom of Saudi Arabia. 24-27 November 2013
Background
The genetically polymorphic cytochrome P450 enzymes
are involved in the metabolism and elimination of a num-
ber of widely used drugs. CYP3A5 exhibits remarkable
inter-individual differences in the pharmacokinetics of
Carbamazepine [1]. The present study was undertaken to
investigate the effects of CYP3A5 on the pharmacokinetics
of antiepileptic drug Carbamazepine in the epileptic
patients showing toxicity.
Materials and methods
30 epileptic individuals who had developed toxicity to car-
bamazepine and 30 control epileptic subjects who had not
developed toxicity to carbamazepine were genotyped for
CYP3A5 polymorphisms by polymerase chain reaction-
restriction fragment length polymorphisms (PCR-RFLP
Method). Carbamazepine plasma levels were analyzed by
reversed phase HPLC method and pharmacokinetic para-
meters such as area under the concentration curve (AUC),
maximum concentration (Cmax), time to Cmax (tmax)
and half-life (t1/2) were estimated by non-compartmental
analysis using PK SOLUTIONS® software.
Results
A significant correlation was observed in the frequency of
homozygous CYP3A5 mutant allele (P <0.01) among the
carbamazepine toxicity and controls. The pharmacoki-
netics parameters of carbamazepine in homozygous
mutant group showed longer half-life (t ½ = 17 hrs) and
less clearance rate (CL =1.5 L/hr) when compared to wild
type group ( t ½ =12.8 hrs, CL = 2.9 L/hr).
Conclusions
Our findings suggest that the CYP3A5 Genetic Poly-
morphisms plays a significant role in the steady state con-
centrations of carbamazepine and thereby having impact
on toxicity in epileptic patients.
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